Evaluate the fPSA for Discriminate between Prostate Cancer Patients (PCa) and Benign Prostatic Hyperplasia (BPH) Depending on PSA Fucosylation by Using Nano-Lectin Immunoassay

Abstract

Aamer M. Ali*, Omar F. Abdul-Rasheed, Ahmed Turki Obaid.

Background: The objective was to evaluate the fPSA for discriminate
between prostate cancer patients (PCa) and benign prostatic
hyperplasia (BPH) depend on the variations in PSA fucosylation
(Fucα1-6/3GlcNAc carbohydrates) by using Aleuria aurantia lectin
(AAL) .
Materials and Methods: The new method lectin-immunoassays were
established for the investigation of PSA fucosylation by measuring
the fluorescence of Eu(III)-chelate-labeled nanoparticles by microplate
flourometer. To the identification of Fucα1-6/3GlcNAc carbohydrates
on PSA surface , the lectin-immunoassays using free PSA specific
monoclonal antibody as acapture and AAL coupled with Eu(III)-chelatelabeled
nanoparticles using as probe for detecting fPSA .
these methods compared with conventional immunoassay ELISA
Result and discussion: The nanoparticle-based lectin-immunoassay
method we showed a statistical significant (p < 0.001) in fPSA level
depend on the fucosylation from PCa patients compared to healthy
control, and also clear significant (p < 0.001) when comparing HBP
patients to PCa patients but HBP compared with healthy control there
is non-significant the (p=0.086) in the nanoparticle-based lectinimmunoassay
methods. while in the immunoasssy ELISA was
showed deffrent result .